European IMI-consortium to study therapy resistance in cancer


A major consortium led by Oncode and AstraZeneca will study treatment resistance in cancer over the coming five years, thanks to funding provided by the European Innovative Medicines Initiatives. Rene Bernards will be representing the NKI. His lab will investigate ways to detect vulnerabilities of these resistant cells.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.